Segment Information and Concentration of Business Risk

3 Months Ended

Mar. 31, 2017

Segment Information and Concentration of Business Risk [Abstract]

Segment Information and Concentration of Business Risk

7. Segment Information and Concentration of Business Risk

We have two reportable segments Ionis Core and Akcea Therapeutics, our wholly owned subsidiary. Segment income (loss) from operations includes revenue less operating expenses attributable to each segment.

In our Ionis Core segment we are exploiting a novel drug discovery platform we created to generate a broad pipeline of first-in-class and/or best-in-class drugs for us and our partners. Our Ionis Core segment generates revenue from a multifaceted partnering strategy.

We formed Akcea to develop and commercialize drugs for patients with serious cardiometabolic diseases caused by lipid disorders. Moving our lipid drugs into a company that we own ensures that our core focus at Ionis remains on innovation while allowing us to maintain control over and retain more value from our lipid drugs.

The following table shows our segment revenue and loss from operations for the three months ended March 31, 2017 and March 31, 2016 (in thousands), respectively.

March 31, 2017	Ionis Core		Akcea Therapeutics			Elimination of Intercompany Activity			Total
Revenue:
Commercial revenue:
SPINRAZA royalties		5,211		—			—			5,211
Licensing and other royalty revenue		3,547		—			—			3,547
Total commercial revenue		8,758		—			—			8,758
R&D revenue under collaborative agreements	$	143,425	$	9,597		$	(51,476	)	$	101,546
Total segment revenue	$	152,183	$	9,597		$	(51,476	)	$	110,304
Income (loss) from operations	$	73,832	$	(59,873	)	$	30		$	13,989

March 31, 2016	Ionis Core			Akcea Therapeutics			Elimination of Intercompany Activity			Total
Revenue:
R&D revenue under collaborative agreements	$	35,214		$	—		$	—		$	35,214
Licensing and other royalty revenue		1,660			—			—			1,660
Total segment revenue	$	36,874		$	—		$	—		$	36,874
Loss from operations	$	(38,567	)	$	(16,049	)	$	(36	)	$	(54,652	)

The following table shows our total assets by segment at March 31, 2017 and December 31, 2016 (in thousands), respectively.

Total Assets	Ionis Core		Akcea Therapeutics		Elimination of Intercompany Activity			Total
March 31, 2017	$	1,202,164	$	132,982	$	(251,150	)	$	1,083,996
December 31, 2016	$	1,067,770	$	10,684	$	(165,987	)	$	912,467

We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as ten percent or more of our total revenue, was as follows:

	Three Months Ended March 31,
	2017		2016
Partner A		59 %		3 %
Partner B		18 %		58 %
Partner C		4 %		14 %

Contracts receivables from one significant partner comprised approximately 92 percent of our contracts receivables at March 31, 2017. Contracts receivables from two significant partners comprised approximately 92 percent of our contracts receivables at December 31, 2016.